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Abstract
Background: Currently the leading cause of global disability, clinical depression is a heterogeneous condition
characterised by low mood, anhedonia and cognitive impairments. Its growing incidence among young people,
often co-occurring with self-harm, is of particular concern. We recently reported very high rates of depression
among first year university students in Northern Ireland, with over 25% meeting the clinical criteria, based on DSM
IV. However, the causes of depression in such groups remain unclear, and diagnosis is hampered by a lack of
biological markers. The aim of this exploratory study was to examine DNA methylation patterns in saliva samples
from individuals with a history of depression and matched healthy controls.
Results: From our student subjects who showed evidence of a total lifetime major depressive event (MDE, n = 186)
we identified a small but distinct subgroup (n = 30) with higher risk scores on the basis of co-occurrence of self-
harm and attempted suicide. Factors conferring elevated risk included being female or non-heterosexual, and
intrinsic factors such as emotional suppression and impulsiveness. Saliva samples were collected and a closely matched
set of high-risk cases (n = 16) and healthy controls (n = 16) similar in age, gender and smoking status were compared.
These showed substantial differences in DNA methylation marks across the genome, specifically in the late cornified
envelope (LCE) gene cluster. Gene ontology analysis showed highly significant enrichment for immune response, and
in particular genes associated with the inflammatory skin condition psoriasis, which we confirmed using a second
bioinformatics approach. We then verified methylation gains at the LCE gene cluster at the epidermal differentiation
complex and at MIR4520A/B in our cases in the laboratory, using pyrosequencing. Additionally, we found loss of
methylation at the PSORSC13 locus on chromosome 6 by array and pyrosequencing, validating recent findings in brain
tissue from people who had died by suicide. Finally, we could show that similar changes in immune gene methylation
preceded the onset of depression in an independent cohort of adolescent females.
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Conclusions: Our data suggests an immune component to the aetiology of depression in at least a small subgroup of
cases, consistent with the accumulating evidence supporting a relationship between inflammation and depression.
Additionally, DNA methylation changes at key loci, detected in saliva, may represent a valuable tool for identifying at-
risk subjects.
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Background
Depression is a highly prevalent, complex mental health
disorder characterised by a range of debilitating symp-
toms. It affects over 300 million people globally [1] and
is responsible for more years lost to disability (YLD)
than any other condition, with a total of 76.4 million
YLD [2]. Mental health problems, including depression,
often emerge before age 18 with the period from 18 to
25 having been highlighted as a susceptible time in a
person’s life [3]. In particular, high prevalence rates of
mental health problems and suicidality have been found
among university students [4, 5]. Northern Ireland (NI)
has one of the highest incidences of mental illness in
Western Europe [6] and the highest rate of suicide in
the UK, a rate which continues to increase [7]. The
trans-generational impact of the years of conflict in NI
have been mooted as one potential contributor to this
[8]. We recently reported on prevalence rates of mental
health disorders, self-harm and suicidality in a large co-
hort (n = 739) of first year NI university students [9] and
found that, consistent with the other recent studies [10–
13], rates were high, with more than 50% of new under-
graduate students reporting any lifetime mental disorder.
Rates of depression and suicidal ideation were particu-
larly high (24.2% and 31.0% respectively). Consistent
with other studies suggesting that self-harm is the stron-
gest predictor of suicidal behaviour [14–17], 122/155 in-
dividuals who self-harmed (78.7%) reported suicidal
ideation in our cohort [7]. These results highlighted the
high incidence of co-occurring depression, self-harm
and suicide amongst young people entering university in
our study population.
The aetiology of depression is very complex, but epi-
demiological studies indicate that genetic and environ-
mental interactions are both implicated in disease
pathology [18–20]. There is a genetic component to the
aetiology of psychiatric disorders, including depression,
which has been demonstrated in twin and family studies
[21] indicating up to 40% heritability. The most recent
meta-analysis of genome-wide association studies
(GWAS), including 246,363 cases of depression and 561,
190 controls, identified 102 independent regions reach-
ing genome-wide significance associated with depres-
sion, including genes and pathways involved in synaptic
structure and neurotransmission [22]. In terms of
environmental causes, severe childhood adversity and
trauma including both verbal and physical abuse, neglect
and parental mental disorders are also major contribut-
ing factors to the development of mood disorders and
suicidal behaviours [23–25]. Other childhood adversities
of varying severity, e.g. parental loss, bullying and socio-
economic status are all associated with increased inci-
dence of depression in later life [24, 26].
There are several well-discussed theories of depression
including the monoamine theory [27], HPA axis dysreg-
ulation in response to stress [28], and in particular the
emerging role of inflammation [29, 30]. Epidemiological
research indicates that up to 70% of individuals with
autoimmune and inflammatory diseases, such as
rheumatoid arthritis and heart disease, experience de-
pression [31]. Chronic stress, a major risk factor for de-
pression, can activate inflammatory response in both the
periphery and CNS through the hypothalamic pituitary
adrenal (HPA) axis [32]. Impaired negative feedback in
the HPA axis resulting in high levels of cortisol lead to
the production of pro-inflammatory cytokines, chemo-
kines and acute phase proteins from macrophages
through the activation of NF-kB [33, 34]. Peripheral in-
flammatory signals are detected by microglia in the
brain, which then initiate their own inflammatory cas-
cade through the activation of CNS cytokines, reactive
oxygen species (ROS) and reactive nitrogen species
(RNS) [35], ultimately leading to alterations in serotonin
signalling and changes in mood.
Peripheral levels of pro-inflammatory cytokines IL-6
and TNF-α are elevated in depression patients who were
SSRI resistant compared to patients with depression, but
in remission whose cytokine levels were similar to
matched healthy controls [36, 37]. In addition, IL-12 and
IL-4 were found to decrease in patients receiving a
course of sertraline treatment [38]. C-reactive protein
(CRP) is elevated in peripheral blood from depressed pa-
tients and significantly decreased from baseline following
successful treatment with the SSRI, sertraline [37], fur-
ther support for the link between inflammation and de-
pression and the potential use of immune markers to
stratify patients.
Our understanding of these mechanisms on a molecu-
lar level however remains poor. The genes implicated in
each of these are different. For example, polymorphisms
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in components of the serotonin system such as the
serotonin-transporter-linked 5-HTTLPR involved with
monoamine levels affect predisposition to anxiety and
depression [39, 40]. In contrast, polymorphisms in
stress-related genes such as 5-HT transporter and CRF
may instead modify susceptibility to depression accord-
ing to HPA axis models. More recently, there has been
great interest in possible epigenetic rather than genetic
changes to components in either the HPA axis, such as
glucocorticoid receptor (GR), or the inflammation
pathway.
Epigenetic modifications such as DNA methylation, in
contrast to DNA polymorphisms, can be influenced by
environmental factors and provides a potential mechan-
ism through which life events such as childhood trauma
and stress, major risk factors of depression, can lead to
the biological, and ultimately behavioural, changes asso-
ciated with depression [41]. Epigenetic mechanisms
could therefore be a key mediator of the interplay be-
tween biological vulnerability and life events leading to
the behavioural changes seen in depression. In this con-
text, there has been much recent interest in methylation
changes at the glucocorticoid receptor (GR) and at genes
related to corticotropin releasing hormone action, all
with potential roles of an HPA axis model [42–44]. In
contrast, a recent study from Murphy and colleagues
using the Illumina 450K Beadarray chip uncovered in-
stead significant association between self-reported de-
pression and methylation changes at genes related to
immune function in peripheral blood samples, particularly
the LTB4R and TRIM39-RPP21 loci, [45]. An earlier study
by the same team found significant methylation changes
at the PSORC13 gene, involved in the inflammatory skin
condition psoriasis, in completed suicide cases [46]. Given
the differing targets implicated in these studies, further
work in additional cohorts could help to clarify the main
pathways showing epigenetic changes and afford greater
insight into potential mechanisms involved.
As indicated above, we reported high rates of depres-
sion as well as co-occurring self-harm and suicide risk in
a cohort of university entrants [7, 9]. In this study, we
wished to (1) investigate the potential external and in-
ternal drivers of depression with and without experience
of self-harm and a suicide attempt in this cohort; (2)
conduct and initial genome-wide screen for DNA
methylation differences in a subset of cases with highest
levels of risk; (3) verify methylation changes at top-
ranking loci using a second method and (4) compare our
findings to other recent work in the area.
We were able to confirm that a set of shared risk fac-
tors greatly increased the chances of co-occurring de-
pression, self-harm and suicidal ideation. In an initial
comparison of saliva samples from students displaying
all three conditions and a closely-matched set of
controls, we identified significant enrichment for im-
mune response genes among those showing differential
methylation. Closer examination highlighted genes in-
volved in psoriasis, including several novel targets (LCE
and MIR4520A/B). All regions could be verified by pyro-
sequencing. With due consideration of the limitations of
the study, these findings nevertheless suggest a signifi-
cant link between psoriasis and depression, self-harm
and suicidal risk that can be detected in peripheral
tissues.
Results
Risk factors in the student population
In order to determine associations between socio-
demographic variables and depression, suicidality and
self-harm, logistic regression analysis was undertaken
(Table 1). Of the total N=739 students who completed
the survey, 24.2% (n = 186) showed evidence of a life-
time Major Depressive Event (MDE). We attempted to
identify discrete groups within these MDE sufferers
using stratification on the basis of risk factors. Several
demographic risk factors were significantly correlated
with depression, self-harm or suicide attempt, or a com-
bination of these three. In particular, females were more
likely to develop depression with comorbid suicide at-
tempt and self-harm (OR = 3.082, p < 0.05), in compari-
son with males. Older students (>21 years old) were
nearly twice as likely to have depression (OR = 1.921, p
< .05), compared to students under the age of 21. In
contrast to heterosexual students, those who stated they
were non-heterosexual were nearly four times more
likely to have experienced depression with comorbid sui-
cide attempt and self-harm (OR = 3.384, p < 0.05). Inter-
estingly, none of the extrinsic factors examined
including finances, bullying or maltreatment, were sig-
nificantly correlated with depression, self-harm and/or
suicidality. However, in relation to intrinsic factors such
as emotional regulation, students who indicated suppres-
sion were more likely to have depression with co-
occurring suicide attempt and self-harm (OR = 1.128, p
< 0.01), compared to those who reported reappraisal,
which was a protective factor (OR = 0.924, p < 0.01).
All values represent odds ratio; SH self-harm; signifi-
cant results in bold; *p < 0.05, **p < 0.01
Selection of cases and controls
The logistic regression results suggested a particularly
high-risk subpopulation within our study, namely stu-
dents reporting depression, self-harm and suicidal idea-
tion, which might display epigenetic differences from
healthy controls. Of the 739 fully completed Student
Wellbeing survey responses a total of only 30 partici-
pants reported depression, self-harm and a suicide at-
tempt. As age, gender and smoking status are known
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confounders in DNA methylation analyses [47, 48], we
chose 16 cases for which we could identify closely
matched controls based on these criteria, where controls
had no life-time history of mental health problems
(Table 2). The average age in both groups was 23 years
(± 5.4), and they contained equal numbers of males (4)
and females (12) each, as well as an identical spread of
smoking status (Table 2). All cases had also experienced
MDE in the 12 months prior to the survey. The average
age of onset of depression was 14, average age of suicide
attempt and onset of self-harm was 16 years. On aver-
age, cases had experienced a MDE for at least two weeks
for an average of 7 years since onset. Saliva samples
from these participants were collected and DNA isolated
from the samples using standard protocols as described
under methods below. Following quality control checks
on the DNA, it was then subjected to genome-wide
methylation analysis using the Infinium Methylation
EPIC 850K Beadchip array.
Gains in methylation at immune response genes
Principal component analysis of the methylation status
of all 32 samples using the RnBeads analysis package
[49] in RStudio demonstrated separation by gender
which confirmed established sex differences in methyla-
tion (Fig. 1a), but not by smoking status or age (not
shown), which indicated that these latter are not major
confounding factors in this study. As a control, a
quantile-quantile plot was carried out, which showed no
evidence of stratification effects among the samples







Dep and attempt with
no self-harm
N = 739 (n = 92) (n = 30) (n = 51) (n = 13)
Demographic risk factors
Gender
Female 1.127 3.082* 1.635 1.188
Male 1.0 1.0 1.0 1.0
Age
21 and over 1.921* 1.161 0.796 3.996
Under 21 1.0 1.0 1.0 1.0
Sexuality
Non-heterosexual 1.164 3.384* 1.076 1.872
Heterosexual 1.0 1.0 1.0 1.0
Extrinsic risk factors
Finances
Enough 0.638 0.939 1.014 1.363
Comfortable 0.816 0.540 0.618 0.000
Well to do 0.308 1.049 1.024 4.438
Poor 1.0 1.0 1.0 1.0
Bullying
Physical bullying 1.023 1.172 0.825 1.454
Verbal bullying 1.134 1.169 1.319 1.037
Ignoring bullying 1.100 1.033 1.409 1.000
Cyber bullying 0.811 0.961 0.983 1.253
Maltreatment
Physical Abuse 0.642 0.879 0.883 0.394
Emotional Abuse 1.334 1.540 1.195 1.588
Intrinsic risk factors
Impulsivity 1.111 1.659** 1.129 0.892
Emotion regulation
Reappraisal 1.010 0.924** 0.973 0.986
Suppression 1.074** 1.128** 1.016 1.043
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(Suppl. Fig.1). Among the female participants, there was
also reasonable separation between cases and controls
(Fig. 1a), with female cases clustered in the negative
quartiles of the PCA and female controls towards the
positive quartiles.
Given that females are at higher risk of co-occurring
depression, self-harm and suicide attempt (Table 1) and
the separation of cases and controls among females in
the PCA (Fig. 1a), we concentrated further bioinformat-
ics analysis on female samples. RnBeads used a combin-
ation of the difference in mean methylation (beta value),
the quotient of mean methylation and the p value to
rank the sites showing differential methylation, which
we and others have found to be a more reliable indicator
of biologically significant differences than p value alone,
which often highlighted sites showing very small differ-
ences in methylation unlikely to be of functional signifi-
cance. A scatterplot of the top 1000 ranked CpG sites
with differential methylation between cases and controls
in females displayed predominantly gains of methylation
in the cases sample group (Fig. 1b).
In order to determine common features between the
top ranking differentially methylated sites, gene ontology
(GO) analysis for genes gaining methylation was carried
out using DAVID software [50] which indicated strong
enrichment scores for immune response terms (Fig. 1c).
Common GO term for both promoters and genes in-
cluded immune system process (GO:0002376), immune
response (GO:0006955), cell activation (GO:0001775)
and regulation of immune system process (GO:
0002682), with very low predicted false discovery rates





Age, mean (range ± SD) 23 (18–32 ± 5.4) 23 (18–32 ± 5.0)
Gender
Male (%) 4 (25) 4 (25)
Female (%) 12 (75) 12 (75)
Smoking status
Past (%) 1 (6.2) 1 (6.2)
Daily (%) 6 (37.6) 6 (37.6)
Occasional (%) 1 (6.2) 1 (6.2)
Never (%) 8 (50) 8 (50)
Physical health
Infectious (%) 0 (0) 0 (0)
Blood or immune (%) 0 (0) 1 (6.2)
Endocrine (%) 0 (0) 0 (0)
Eye or ear (%) 1 (6.2) 0 (0)
Neurological (%) 0 (0) 0 (0)
Heart or circulatory (%) 0 (0) 0 (0)
Respiratory (%) 0 (0) 2 (12.5)
Digestive (%) 0 (0) 2 (12.5)
Skin (%) 0 (0) 5 (31.3)
Musculoskeletal (%) 0 (0) 2 (12.5)
Fig. 1 Methylation gains at immune response genes in stratified cases. a Principal component analysis (PCA) for all methylated sites of the 32
samples from subjects showing comorbid depression, self-harm and suicidal attempt compared to healthy controls. This indicated clear
separation by gender, but also between cases (orange) and controls (green) for females. b Scatterplot of differential methylation, with the top
1000 probes in red. c Gene ontology analysis of the top differentially methylated gene bodies shows significant enrichment for immune system
response terms. d Reanalysis of array data using an in-house Galaxy workflow. Differentially methylated probes whose coordinates matched
genes from the top two ranks in c (relating to immune system response) were identified. Median methylation levels were assessed and again
showed a significant difference between cases and controls (**p < 0.01)
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(FDR). Promoters and genes which showed loss in
methylation were instead enriched for GO categories re-
lated to epidermal and keratin genes, but with higher
FDR rates indicating lower likelihood of being true hits,
most likely due to the smaller number of genes showing
loss (data not shown).
To verify gains in methylation using a different bio-
informatic approach, gene names common across the
GO categories related to immune response were com-
piled (Table S1). We used an in-house developed work-
flow in Galaxy termed CandiMeth (Thursby and Walsh,
in prep) to map differentially methylated probes to the
human genome map, as previously described [51], found
those which fell within promoters (defined as starting
500 bp 5’ of the first exon) of these immune genes, and
extracted the mean methylation values in cases and con-
trols. Comparison of the average methylation across
these genes between the two groups confirmed signifi-
cant (p < 0.01) gains in mean methylation levels in the
cases relative to the controls (Fig. 1d).
Top-ranking regions include several loci linked with
psoriasis and skin conditions
To examine more closely the immune response targets
identified by the genome-wide scan, and to identify
those where methylation differences could be verified in
the laboratory, we ranked the top hits showing gains in
methylation by the magnitude of the difference in
methylation (Δβ), both at gene bodies (Fig. 2a) and pro-
moters (Fig. 2b). The Late Cornified Envelope-3C
(LCE3C) and -3B (LCE3B) loci featured at the top of
both lists and showed substantial gains in methylation (>
10%) in cases versus controls (Fig. 2a, b). These genes
are part of a family which encode components of the
stratum corneum of the skin and are thought to play a
role in skin differentiation. The LCE3 genes in particular
have been linked to the development of psoriasis, a
chronic inflammatory skin disease characterised by
hyperproliferation of the epidermis and changes to kera-
tinocyte differentiation [52]. Many of the LCE family
members are clustered together on chromosome 1q21.3
in a region known as the epidermal differentiation com-
plex (EDC) which contains multiple other genes
expressed in the upper layers of the skin. A small dele-
tion encompassing LCE3B and part of LCE3C (LCE3C_
LCE3B-del) is found in a substantial fraction of psoriasis
sufferers [52–54]. As hemizygosity would affect methyla-
tion ratios, we checked for copy number variation
(CNV) at this locus in our participants using the R pack-
age DNAcopy. No evidence for a CNV on chromosome
Fig. 2 Top-ranking regions are linked to the immune condition psoriasis. a The top gene body regions identified from the differential
methylation analysis listed by percentage change in methylation (% change). Absolute levels of methylation in % for cases and controls are also
shown. The associated gene names from the array manifest file are listed at left and include three with links to psoriasis (LCE3C, LCE3B, MIR4520A/
B). b Promoters with the largest delta beta gain in methylation levels: DEFB104B is also linked to psoriasis c Map of part of the Epidermal
Differentiation Complex on chromosome 1 from UCSC (GRCh37/hg19 human assembly) showing some of the LCE gene cluster (RefSeq track at
bottom). The track at top shows the locations of probes from the EPIC array in black (EPIC probes). Below, sites showing differential methylation
between cases and controls have been mapped: sites gaining are above the line (blue) and losing below the line (red), with size proportional to
change. A scale with maximum and minimum change (Δ) is shown at left. Clusters of probes gaining methylation are seen across LCE3A-3C (left)
and at LCE1D (right). A scale bar is shown at top; kb, kilobase
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1q21 was found using this method, despite successfully
detecting an isolated CNV in one patient on chromo-
some 5 (Fig.S2).
We mapped the differentially methylated sites identified
in the screen to the human genome (hg19) and found clus-
ters of sites comprising a differentially methylated region
(DMR) not only at the LCE3A-3B locus, but also further
along in the cluster at the LCE1D-1C locus (Fig. 2c), further
supporting the association of depression with methylation
changes at the LCE genes in this region. In order to confirm
methylation differences at promoter regions, we used a
commercially-available pyrosequencing assay to assess a site
~ 700 bp upstream of the LCE3A transcriptional start site
(Fig. 3a). This site showed a gain of methylation of 18.2% in
cases compared to controls (42.2 vs 24.0), identical to that
seen using the array (18.2% gain: 43.6% vs 25.4%).
Interestingly another locus the microRNA cluster
MIR4520A/B on chromosome 17 (Fig. 2a), which was
identified as a top hit by the genome-wide assay, has also
been linked to psoriasis [55]. We also used a pyrose-
quencing assay (Fig. 3b) to assess the methylation differ-
ence at this region. While absolute levels of methylation
at this site were lower by pyroassay than seen using
the array (controls 16.7% pyro vs 21.95 array; cases
29.2% vs 34.5%), the approximate level of methylation
is similar, and the gains in methylation seen between
controls and cases was almost identical (12.5% pyr-
oassay vs 12.6% array) (Fig. 3b).
Fig. 3 Verification of methylation differences at psoriasis targets. a Top: genomic map indicating the region around the LCE3A gene. Tracks
showing locations of array probes and probes showing differential methylation are as in Fig. 2. The location of the pyrosequencing assay (Pyro)
upstream of the first exon of LCE3A is also shown. Genomic coordinates are as indicated. Bottom: Table comparing methylation levels as % at the
CpG site covered both by an EPIC array probe and the pyroassay, which showed good agreement. b Top: genomic map showing the region on
chr17 containing the MIR4520A/B locus (aka RefSeq MIR4520-1 and -2) and neighbouring genes. Tracks and key are as in a above. Bottom: Table
comparing methylation at the CpG covered both by the array and the pyroassay, which were again concordant
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Validation of the PSORS1C3 DMR
Recently an independent epigenetic screen by Murphy
and colleagues (2017) also identified a link between
psoriasis and depression. On comparing methylation in
brain regions BA11 and BA25 of depression-suicide
cases and normal controls, they identified Psoriasis Sus-
ceptibility 1 Candidate 3 (PSORS1C3) as one of the top
hits [46]. A region comprising 12 CpG sites across the
PSORS1C3 locus showed loss of methylation (rather
than gain) in depression-suicide cases compared to con-
trols in that study. While this locus was not identified as
a major target in our screen, there were a number of dif-
ferences in sample size, tissue type and clinical diagnos-
tics used which could account for this. An examination
of the differentially methylated sites in our study con-
firmed however that there were a number of CpG show-
ing loss of methylation immediately upstream of the
PSORSC1C3 gene in an area likely to contain the pro-
moter (Fig. 4a), with a maximum loss seen of 12.7%. To
verify that there were differences in methylation between
our cases and controls at this region, we designed a pyr-
oassay for this site, which confirmed a loss of methyla-
tion. The results again showed good concordance both
in direction (loss) and magnitude (12.0% vs 12.7%) be-
tween the pyroassay and the array (Fig. 4b).
Alterations to immune genes precede development of
depression in an independent cohort
One possible complication with regards to working with
saliva is that the samples may differ significantly in the
ratios of different cell types present. While surrogate
variable analysis as performed can compensate for such
hidden variables, an estimate of cell counts in the sam-
ples would be valuable. However, these could not be
done on saliva, so we sought instead to estimate cell ra-
tios using methods based on the array data alone, a so-
called reference-free method. These methods are based
on the observation that some methylation sites on the
array show characteristic levels of methylation in specific
tissues, independently of effects at other sites [56]. We
employed the recently-developed EpiDISH algorithm
[57] which is more suitable for saliva than the original
methods developed for blood. As can be seen in Fig. 5a,
EpiDISH indicated that the saliva samples from the Stu-
dent Wellbeing Study cases had significantly different
proportions of epithelial (p = 0.011, Kruskal-Wallis H =
6.16) and immune cells (p = 0.013, Kruskal-Wallis H =
6.453) from the controls. This suggested that some of
the immune gene signature seen in our cohort may be
due to differences in immune status at the time of sam-
ple collection in the cases versus controls. While this
finding is valuable in itself as a biomarker, most of the
changes seen in overall methylation and in specific clas-
ses of genes will be independent of the small number of
sites used to identify tissue type. We wished therefore to
further investigate if some of these methylation changes
in immune genes may precede the overt changes in cell
numbers and be linked to earlier stages in the develop-
ment of depression.
A recently published study examined methylation pat-
terns in female children, born to mothers with major de-
pressive disorder (MDD), who were at increased risk of
developing depression [58]. Saliva was collected from
these girls ~ 13 years and analysed with the Illumina
Fig. 4 Replication of differential methylation at PSORSC13 in this cohort. Top: region around the PSCORSC13 gene, first identified as showing loss
of methylation in a separate cohort of depressed subjects who had died by suicide. Symbols are as in Fig. 2 above, with addition of a track for
CpG islands (green) often found near promoters. A cluster of probes showing loss of methylation (red, below line) are also evident in our cohort
upstream of the first non-coding exon. A pyroassay (pyro, black square) was designed to determine methylation at the individual CpG just 5’ of
the island showing greatest loss on the array. Bottom: Table comparing loss of methylation at the indicated CpG site on the array and by
pyroassay, which were again in close agreement
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EPIC chip, then the children followed longitudinally,
with many developing MDD. Due to the excellent match
with phenotype, gender, tissue and method of assess-
ment this is an ideal cohort for examining changes
which may occur prior to the onset of depression. We
obtained raw data from the authors and analysed them
using the same pipeline described above. Looking at the
children who went on to develop MDD, despite the fact
that they show no sign of differences in cell counts be-
tween cases and controls (Fig. 5b), we found that many
of the same top GO categories involved immune system
response (Fig. 5c). Likewise, there was overlap between
many of the top-ranked gene bodies (Fig. 5d) and pro-
moters (Fig. 5e) showing gain in methylation between
the two studies, with many of the best hits (LCE3B,
LCE3C, PRAMEF23, DEF104B) being common to both,
supporting our theory that immune gene alterations may
prefigure MDD.
Discussion
Our previous work identified a high rate of depression
among University students in Northern Ireland [9].
Here, we further analysed this cohort and found that
while there were several extrinsic or intrinsic risk factors
Fig. 5 Alterations to immune genes precede development of depression in an independent cohort. a EpiDISH cell-type fraction estimation for
epithelial and immune cells for the Student Wellbeing Study (SWS); differences were significant by Kruskal-Wallis test (*p < 0.05). b EpiDISH
analysis of saliva samples taken from at-risk adolescent girls prior to development of major depressive disorder (MDD; 58); ns, not significant, KW
test. c Gene ontology analysis of the top 3000 ranked differentially methylated gene bodies from the MDD study shows significant enrichment
for immune system response terms. d Top 1000 gene bodies gaining methylation in the SWS and the MDD cohorts showing overlap; top hits
already identified in the SWS cohort are indicated. e Top 1000 promoter regions indicating shared targets between the two cohorts as in d
Lapsley et al. Clinical Epigenetics           (2020) 12:85 Page 9 of 16
which were significantly correlated with depression on
its own, or depression and any one other feature, de-
pressed students with both self-harm and suicide at-
tempt formed a distinct sub-group with higher risk
scores. Significant risk factors for this group included be-
ing female or non-heterosexual, and having higher impul-
sivity and emotional suppression with poorer re-appraisal
ability. Hypothesizing that this much smaller sub-group
might also show distinct epigenetic marks, we looked for
differential methylation patterns in saliva samples from
this group. Female cases separated from controls and
showed overall tendency to gain in methylation. Methyla-
tion differences were significantly enriched in immune-
related genes, with a number of top hits, including the
LCE3 genes and MIR4520A/B, being linked to the inflam-
matory skin condition psoriasis. We confirmed methyla-
tion differences at several loci by pyrosequencing.
Additionally, the psoriasis gene PSORS1C3, recently iden-
tified as showing altered methylation in post-mortem
brain from suicide completers, was also differentially
methylated in our saliva samples. Finally, we saw alter-
ations in methylation at some of the same immune-
related genes in an independent cohort of teenage girls
prior to onset of depression, suggesting these changes are
occurring early in the etiology of the disease.
One of our major findings was the clear differential
methylation between cases and controls we identified in
immune-related genes. Depression has been previously
linked with several chronic inflammatory conditions in-
cluding diabetes, rheumatoid arthritis and cardiovascular
disease [31, 59]. Inflammatory cytokines, IL-6, TNF-α
and IFN-γ are consistently upregulated in individuals
with depression [32, 60] and many antidepressant medi-
cations have anti-inflammatory effects [61]. Further-
more, recent methylome analysis of whole blood also
reported that depression-related methylation differences
were enriched in pathways related to immune function
[45], consistent with what we have identified for the first
time in saliva. DMRs in immune response genes and
their link to immune dysregulation warrant further in-
vestigation as potential biomarkers for depression.
Psoriasis is one of the most common inflammatory
skin conditions, and affects up to 125 million people
worldwide [62]. While being noncontagious and nonle-
thal, it nevertheless can be painful and disfiguring and
can lead to severe disruptions in everyday social interac-
tions and personal relationships. Psoriasis tends to de-
velop between the ages of 15 and 25 and can lead to an
impairment of social development due to attendant feel-
ings of self-consciousness and embarrassment [63]. The
average age of onset for psoriasis therefore shows not-
able overlap with that for depression, commonly occur-
ring around 15 years old [3]. In a large UK population-
based study individuals with severe psoriasis were also
reported to have an increased susceptibility to depres-
sion, anxiety and suicidality [64]. In that study, patients
with psoriasis had a 39% increased chance of depression,
which increased to 72% for severe psoriasis. Significantly,
randomized controlled trials have shown that control of
psoriasis symptoms can lead to improvements in psy-
chological outcomes [65, 66]. Paediatric patients in par-
ticular have been shown to be at increased risk of
developing depression [67]. Individuals with psoriasis
display fatigue and sleep deprivation, which has been
linked to the concomitant pruitis (itching) and pain and
is linked to depression and obstructive sleep apnea in
this group [68]. Insomnia has been recently highlighted
as a particular risk factor for self-harm and suicide in
university students [7, 69].
As indicated earlier, genes in the LCE cluster, and par-
ticularly LCE3 homologues, have been strongly linked
with psoriasis. The genes lie in the Epidermal Differenti-
ation Complex (EDC) on chromosome 1, and genome-
wide association studies (GWAS) have identified a major
psoriasis susceptibility locus (PSORS4) in this region [70,
71]. A separate GWAS in the Chinese Han population
identified two SNPs in the LCE3A gene, and three in
LCE3D as particularly associated with psoriasis. The
EDC also contains other skin genes such as Filaggrin
family member 2 (FLG2) and Cornulin: interestingly ex-
perimental disruption of the skin barrier resulted in
down-regulation of LCE5A, LCE2B and FLG2 but upreg-
ulation of LCE3A, Involucrin and Hornerin [72]. LCE3
genes show marked difference in expression between
psoriatic lesions and normal skin, but not between pre-
lesional skin and control [72–74], consistent with roles
in skin repair rather than development per se. A small
deletion encompassing parts of LCE3C and LCE3B
(LCE3C_LCE3B-del) has also been identified as a risk
factor for psoriasis in a number of populations [52].
While we tested for CNV affecting this region in our co-
hort, we found no evidence for any deletions. The LCE
cluster has also been reported to interact epistatically
with the PSORS1 locus at the HLA-complex on
Chromosome 1 [53, 75].
Furthering the link with psoriasis, other top hits from
our screen are also connected with this condition. The
MIR4520A/B locus, which produces two microRNA
miR4520A and –B, was also a top-ranking region from
our screen. While little is currently known about this
microRNA, next-generation sequencing of small RNAs
from normal versus psoriatic skin highlighted miR4520A
as one of the most abundant novel miRNA expressed in
psoriatic skin [55] which was significantly downregulated
in psoriatic lesions. Although it has not been firmly
established whether transcription of this miR is epige-
netically controlled, increased DNA methylation at this
region may indicate downregulation of this gene in our
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cohort. Another top hit was DEFB104B, which is a beta-
defensin and part of a family of antimicrobial and cyto-
toxic peptides made by neutrophils. Defensins are
expressed during inflammatory conditions, including
psoriasis [76]. A total of 4 CpG sites were hypermethy-
lated at the promoter regions of DEFB104B in our cases,
suggesting perhaps a form of silencing or reduced
mRNA expression and thus reduction/suppression of
the innate immune response in depressive cases.
As detailed above, a number of loci involved in psoria-
sis were identified among our cases with depression and
co-occurring self-harm and suicide attempt. Recently,
Mill and colleagues (2017) compared methylation in two
cortical brain regions from depressed suicide completers
and non-psychiatric sudden-death controls and also
identified a psoriasis susceptibility locus PSORS1C3 as
the main target affected [46]. They found a loss of
methylation at a DMR upstream of the gene, which they
verified by pyrosequencing and could replicate in a sec-
ond set of suicide samples. While PSORSC1C3 was not
identified as a high-ranking DMR in our screen, there
were a number of important differences between our
studies: (1)we were using saliva samples not brain, and
tissue type is known to have a major effect on methyla-
tion patterns [77] as seen even between brain regions
[46]; (2) our samples were from subjects reporting sui-
cide attempt at most, not completion and (3) there were
a number of technical differences in diagnosis, process-
ing and analysis, including the use of different chips
(450K vs 850K EPIC). Nevertheless, on examination of
the PSORS1C3 locus in our cohort we found a DMR at
this region which also showed loss of methylation in our
samples (in contrast to the gains seen at other loci). We
could also verify this using pyrosequencing, with good
agreement in direction and magnitude of difference. These
results are important as they (1) confirm methylation
changes at this locus in another cohort displaying depres-
sion; (2) further link psoriasis, depression and suicidal
thoughts and behaviour; (3) indicate that changes seen in
the brain may also be mirrored in peripheral tissues such
as saliva (4) suggest the change precedes death by suicide
and therefore may have utility as a predictive tool.
The exact nature of the overlap between depression and
psoriasis warrants further investigation. Traditionally, de-
pression was thought to be a secondary consequence of
living with a chronic physical condition such as psoriasis.
However, the accumulating evidence that depression itself
has an inflammatory component suggests that there may
be common aetiology which can lead to mental health dis-
orders, physical health problems, or both in a given indi-
vidual. In our current sample, none of the depressed
group reported psoriasis, indicating that while there is
overlap in risk on a molecular level this does not necessar-
ily manifest as co-occurrence of the two conditions.
While replication of the PSORSC13 finding in saliva is
encouraging, there has been debate over whether find-
ings in peripheral tissue in general will parallel those in
the organ most likely to be primarily involved, in this
case the brain. A recent study evaluated DNA methyla-
tion patterns in the blood and saliva using the 450K
BeadChip to assess the correlation of the two sample
sources with secondary data from brain tissue. Although
concordance was poor overall, methylation patterns in
saliva were more similar to the brain methylome than
blood [78]. The development of biomarkers that can be
used to improve the diagnosis of depression, or those
predictive of response to treatment, requires them to be
easily accessible for sampling, so identification of reliable
markers of depression in the periphery have more clin-
ical utility than those in the brain. Saliva is a very prom-
ising potential biomarker discovery tissue due to the
non-invasive sampling method. A concern is whether
cell composition differences between cases and controls
might be a confounding effect. The collection method
utilised here involved the lysis of the cells so the specific
cell types present could not be directly assessed. EpiD-
ISH analysis indicated that the saliva samples from the
cases had different proportions of both cell types from
the controls, and that these were significant. Thus, it is
likely that the methylation profile in part may reflect a
difference in cell count in the cases vs controls. From
the point of view of a biomarker, this is still a valuable
finding as it can help to identify people with depression
based on a heightened altered cell profile. On another
level, we must consider that the surrogate variable ana-
lysis (SVA) and correction applied to our cohort will
have accounted in part for this, suggesting that the im-
mune gene hits highlighted in the analysis are genuine
targets: these two levels of information are analogous to
the cell count estimators such as EpiDISH, which can
determine cell types independently of the top hits in the
differential methylation analysis. Furthermore, immune
genes were the top GO categories, and LCE and other
immune genes the top hits, in the independent MDD
cohort where there was no evidence of cell count skew-
ing and prior to MDD onset, strongly supporting an
underlying immune system link with depression.
The current exploratory study was carried out on a
relatively small subgroup from the larger available stu-
dent cohort as an initial investigation into the viability of
using DNA methylation in saliva samples as potential
biomarkers of depression. However, we have taken a
stratified approach here in sub-classifying the cases of
depression and, using logistic regression identified the
small group of students who represent the most severe
cases of depression with self-harm and suicide attempt.
Our sample screened by array here represented more
than half (16/30) of that high-risk subgroup: by limiting
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the samples chosen we could more closely match these
cases to controls with no history of mental disorders in
terms of known confounders in methylation analysis,
namely age, gender and smoking. The stratification ap-
proach may explain why clear differences were observed
between the groups despite the small sample size overall.
Significant hits were determined using a combined rank
approach across adjacent sites, which took into account
not only p value, but also magnitude and quotient for
the changes in methylation, and is considered a more re-
liable indicator of biologically meaningful differences
than p value alone [79]. Methylomic profiling of add-
itional samples across a broad spectrum of individuals
with depression are necessary to determine whether
these changes are representative of depressive cohorts
generally and to assess their utility as biomarkers.
Conclusions
While this study is exploratory in nature, and has a num-
ber of caveats as indicated above, it nevertheless shows a
novel linkage between epigenetic changes detected in sal-
iva, and a particular category of depression with self-harm
and suicidal attempt. Furthermore, our study clearly im-
plicates changes at genes involved in the chronic inflam-
matory condition psoriasis, supporting emerging evidence
from a number of epidemiological studies. Future work
will include the analysis of a larger cohort if possible, as
well as investigating specific intrinsic influences such as
childhood adversity, and other clinical/phenotypic infor-
mation. Additionally, it will be valuable to explore the po-
tential mechanistic role of methylation in controlling
transcription from these loci. Further analyses will also de-
termine whether these markers have clinical utility in




Ethical approval was obtained from Ulster University Re-
search Ethics Committee (REC/15/0004).
Design
The Ulster University Student Wellbeing Study (UUSWS)
has been described in detail elsewhere [7, 9] and was
conducted as part of the WHO World Mental Health
International College Student Project (WMH-ICS). The
UUSWS study is being conducted as part of the WHO
World Mental Health International College Student Pro-
ject (WMH-ICS). An observational, longitidunal cohort
study design is used for all studies. Prospective studies,
such as this, can be very benefical in that recall issues are
minimised, sequences or patterns of events can be estab-
lished and causal relationships may be inferred.
Recruitment
All students commencing Ulster University in Septem-
ber 2015 were emailed a participant information sheet.
First year students were recruited during registration
where they gave written consent, provided a saliva sam-
ple and were given a unique, anonymous number to
complete an online mental health survey clinically vali-
dated against the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV) [80].
Survey responses
The survey instrument was adapted from the WMH Com-
posite International Diagnostic Interview (CIDI), version
3.0 [81], designed to be validated against the criteria of
ICD-10 and DSM-IV disorders. Although these measures
are self-report, good concordance has been found between
the CIDI and clinical assessments [82]. Participants com-
pleted a section on emotional problems including depres-
sion, bi-polar disorder, anxiety, panic attacks or panic
disorder and other serious emotional problems. Suicidal
behaviour and non-suicidal self-injury (NSSI) questions
were included from the Self-Injurious Thoughts and Be-
haviours Interview [83]. Impulsivity was measured by ask-
ing the participants if they often act without thinking, a
Likert scale ranging from 1 ‘strongly agree’ to 6 ‘strongly
disagree’ from the Student Experience and Student Expec-
tations questionnaire [84]. Bullying was measured by ask-
ing participants how often they experienced the following:
(1) you were bullied at school physically (i.e. repeatedly
punched, shoved or physically hurt)? (2) You were bullied
at school verbally (i.e. teased, called names). (3) You were
bullied at school by someone who purposefully ignored
you, excluded you, or spread rumours about you behind
your back? You were bullied over the internet (e.g. Face-
book, Twitter) or by text messaging? The questionaire
used a Likert scale ranging from 1 ‘very often’ to 5 ‘never’.
These questions were adapted from The Bully Survey [85].
Maltreatment was measured by asking participants how
often they experienced the following using a Likert scale
ranging from 1 ‘very often’ to 5 ‘never’: (1) physical
abuse—you were physically abused at home; (2) emotional
abuse—you were emotionally abused at home. The ques-
tions were adapted from the Adverse Childhood Experi-
ences Scale [86]. Emotion regulation was measured using
the Emotion Regulation Questionnaire, which consists of
two dimensions of emotion regulation, reappraisal (six
questions) and suppression (four questions), related to
how well they control or manage their emotions. The in-
strument utilises a 7-point Likert scale. High scores for re-
appraisal are optimal while low scores for suppression
indicate better emotion regulation strategies [87]. Logistic
regression analysis was used to explore relationships be-
tween socio-demographic risk factors for individuals with
depression, and comorbid suicidality and/or self-harm.
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Case selection
Cases (n = 16) were selected from students who met the
criteria for life-time (LT) major depressive episode, and
who also reported suicide attempt and self-harm. Life-
time depression is determined based on the response to
seven questions (Likert scale) corresponding to DSM-IV
criteria for depression. To calculate LT depression the
first 6 symptoms/questions were recoded to 4 = “all or
most of the time and 0 = none of the time, and summed.
If at least 1 of the first 4 symptoms was “all or most of
the time” and the sum of all six symptoms was at least
15 then participants met the criteria for depression. Sui-
cidality, including thoughts, plans and attempts and self-
harm, was assessed using items from the Self-Injurious
Thoughts and Behaviour Interview [83]. If a participant
responded yes to either of two questions asking about
thoughts of hurting or killing themselves, or responded
yes to direct questions on plan or attempt, they met the
criteria for suicidal behaviour. Self-harm was assessed by
asking the participant the following question: did you
ever do something to hurt yourself on purpose, without
wanting to die? (e.g. cutting yourself, hitting yourself, or
burning yourself)? If they responded yes, they met the
criteria for self-harm and were asked some further ques-
tions with regards to the number of times and what age
this began. Healthy controls (n = 16) were participants
who reported no mental health problems, and strictly
matched by age, gender and smoking status.
Sample collection
Saliva samples were collected using Oragene OG-500
kits (DNA Genotek, Ontario Canada), enabling the self-
collection and stabilisation of DNA at room temperature
as per manufacturer guidelines.
DNA extraction, bisulphite conversion and EPIC Beadchip
Array
Saliva samples were incubated for 2 h at 56 °C, and
DNA isolation carried out with PrepIT.L2P (DNA Geno-
tek Inc., Canada) as per the manufacturer’s instructions.
The purity and integrity of the genomic DNA prepara-
tions were assessed by agarose gel electrophoresis, and
the quantity of DNA was determined using Quant-IT
PicoGreen dsDNA Assay Kit (Invitrogen, Paisley, UK).
In preparation for DNA methylation analysis, 500 ng of
DNA was bisulphite converted using the EZ DNA
Methylation Kit (Zymo Research, CA, USA) according
to manufacturer’s instructions. Genome-wide DNA
methylation profiles were generated using the Infinium
Methylation EPIC Beadchip Array, and the Beadchip im-
ages captured using an Illumina iScan (Cambridge Gen-
omic Services, Cambridge, UK) for matched cases (n =
16) and controls (n = 16).
Bioinformatic analysis
Data was analysed using the RnBeads package (version
1.6.1) [49] on the freely available statistical software plat-
form R (version 3.1.3). All samples passed quality control
and were subjected to pre-processing, which involves fil-
tering of probes and normalisation. Probes removed in-
cluded those with a missing value (NA), probes at SNP-
enriched sites, and bad quality probes determined by
greedycut algorithm. Background correction was carried
out using methylumi.noob v2.32.0 [88] and the methyla-
tion values of the remainder probes were normalized
using bmiq [89]. Copy number variation (CNV) was
assessed using the DNAcopy package v1.60.0 [90]. In
order to account for any hidden confounding variables
in the dataset, surrogate variable analysis was carried out
using the limma method [91]. The methylation inten-
sities for each probe, representing a CpG site, were rep-
resented as β values (ranging from 0, unmethylated, to 1,
fully methylated) and these were plotted against genomic
loci (based on Human Genome Build 19) using an in-
house developed workflow in GALAXY v19.01 (https://
usegalaxy.org/) [92] called CandiMeth (Thursby and
Walsh, in prep) in order to visualise changes in DNA
methylation in UCSC (https://genome.ucsc.edu/) and
quantify differences across specific genomic intervals.
Subsequent gene ontology (GO) analyses were per-
formed using DAVID v6.7 (https://david.ncifcrf.gov/)
[50]. Cell type composition estimation was performed in
RStudio using EpiDISH v2.2.2 [57].
Pyrosequencing
Bisulphite pyrosequencing was carried out in order to ver-
ify changes in methylation at loci of interest from the Infi-
nium MethylationEPIC Beadchip Array. Primers spanning
the probes of interest from the array were designed using
the PyroMark Assay Design Software 2.0 (Qiagen, Man-
chester UK). Bisulfite-treated DNA was PCR-amplified
using the PyroMark PCR kit (Qiagen, Hilden, Germany)
according to manufacturer’s instruction. The primer se-
quences and PCR conditions are summarized in Supple-
mentary Table 1. Amplification was carried out as follows:
95 °C for 15 min, followed by 45 cycles of 95 °C for 30 s,
56 °C for 30 s, and 72 °C for 30 s, with a final elongation
step at 72 °C for 10 min. Pyrosequencing was performed
as per manufacturer’s instructions on the PyroMark Q24
system (Qiagen, Hilden, Germany), and methylation
levels were analysed using PyroMark Q24 1.010 soft-
ware (Qiagen, Hilden, Germany).
Statistical analysis
Differential methylation analysis was conducted on site
and region level for healthy controls and cases samples.
The normalized β values of the Infinium MethylationE-
PIC Beadchip Array data were converted into M values
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(M = log2(β/(1-β)) and differential methylation between
samples (cases vs. healthy controls) was estimated with
hierarchical linear models using limma. On the region
level (i.e. genes, promoters, CpG islands), differential
methylation was computed based on the average differ-
ence in means across all sites in a specified region of the
sample groups and the mean of quotients in mean
methylation as well as a combined p-value, which was
calculated from all site p-values in the region using a
generalization of Fisher's method [93]. In addition, each
region was assigned a rank based on each of these cri-
teria. The smaller the combined rank for a region, the
more evidence for differential methylation it exhibits.
The top 1000 ranking genes of each region was input
into DAVID. We used DAVID software to determine
significance of each gene ontology category, calculated
using a modified Fisher’s exact test (EASE score) which
was FDR-corrected. Pyrosequencing data were analysed
using Student’s t test to identify statistical differences be-
tween cases and healthy controls. EpiDISH data was
analysed using Kruskal-Wallis test to identify statistical
differences between cell type composition for cases and
controls in each cohort. A p value < 0.05 was considered
significant.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13148-020-00877-7.
Additional file 1: Table S1. Pyrosequencing primers.
Additional file 2: Table S2. Immune-related genes analysed for gains
in methylation at promoter.
Additional file 3: Figure S1. Absence of population substructure
effects. A quantile–quantile (QQ) plot showing observed vs. expected −
log10 (p values) for association at all CpG sites. The x-axis shows the ex-
pected −log10 (p value), the y-axis the observed –log10 (p value): the red
line indicates the expected distributions under the null hypothesis and
the black dots were the observed values. A close match at lower signifi-
cance values indicated no systematic inflation of P was seen due to
unaccounted-for stratification effects.
Additional file 4: Figure S2. Absence of deletions or duplications at
top differentially methylated loci. EPIC array probe data was analysed
using the DNAcopy package in R to look for variations indicating copy
number variation (CNV): an example output plot from subject 225
(Healthy Control) is shown. Probe index number is shown along the x-
axis, while gain/loss in copy number, expressed as the log-10 ratio, is
shown on the Y-axis; dots coming away from the line indicate probes
showing gains or losses of signal consistent with regional duplications/
deletions. No significant CNVs were detected in the Epidermal Differenti-
ation Complex (EDC) region on chromosome 1q21, but the approach
successfully detected a CNV on chromosome 5 in one participant (arrow
at right) not overlapping any of the differentially methylated regions,
shown here as a positive control for sensitivity. DNAcopy plots were car-
ried out for all samples and failed to detect copy number variation (CNV)
at other top hits.
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